Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 1/20 | 0.70 |
| ▸ | F10 | P00742 | 1/20 | 0.70 |
| ▸ | PLG | P00747 | 1/20 | 0.70 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.70 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.58 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.58 |
| ▸ | AKR1C3 | P42330 | 4/20 | 0.50 |
| ▸ | CTSB | P07858 | 1/20 | 0.50 |
| ▸ | CASP1 | P29466 | 5/20 | 0.46 |
| ▸ | IL1B | P01584 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL949943 | 1.00 | F2 (0.70) | F2F10PLGPRSS1ITGB3 | |
| SCHEMBL8764289 | 1.00 | F2 (0.70) | F2F10PLGPRSS1ITGB3 | |
| SCHEMBL949942 | 1.00 | F2 (0.70) | F2F10PLGPRSS1ITGB3 | |
| SCHEMBL12450732 | 0.90 | F2 (0.71) | F2F10PLGPRSS1ITGB3 | |
| SCHEMBL13928231 | 0.85 | F2 (0.54) | F2F10PLGPRSS1ITGB3 | |
| SCHEMBL13951111 | 0.85 | F2 (0.54) | F2F10PLGPRSS1ITGB3 | |
| SCHEMBL28706879 | 0.83 | ITGB3 (0.57) | F2F10PLGPRSS1ITGB3 | |
| SCHEMBL28706884 | 0.83 | ITGB3 (0.57) | F2F10PLGPRSS1ITGB3 | |
| SCHEMBL28706887 | 0.83 | ITGB3 (0.57) | F2F10PLGPRSS1ITGB3 | |
| Hydrochloric Acid SCHEMBL7297380 | 0.81 | PLG (0.75) | F2F10PLGPRSS1ITGB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120238749-A1 | INHIBITORS OF INTERLEUKIN-1 BETA CONVERTING ENZYME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-09-20 | — | — | US | disclosed |
| EP-0784628-A1 | INHIBITORS OF INTERLEUKIN-1$g(b) CONVERTING ENZYME | Vertex Pharmaceuticals Incorporated (US) | 1997-07-23 | — | — | EP | disclosed |
| WO-1995035308-A1 | INHIBITORS OF INTERLEUKIN-1β CONVERTING ENZYME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 1995-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120238749-A1 | INHIBITORS OF INTERLEUKIN-1 BETA CONVERTING ENZYME | IL1B, IL1A, IL1R1 | F2 1406/4885F10 1189/4885PLG 360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.